These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12406626)

  • 1. Design and synthesis of 225Ac radioimmunopharmaceuticals.
    McDevitt MR; Ma D; Simon J; Frank RK; Scheinberg DA
    Appl Radiat Isot; 2002 Dec; 57(6):841-7. PubMed ID: 12406626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efforts to control the errant products of a targeted in vivo generator.
    Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
    Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
    Ma D; McDevitt MR; Finn RD; Scheinberg DA
    Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.
    Maguire WF; McDevitt MR; Smith-Jones PM; Scheinberg DA
    J Nucl Med; 2014 Sep; 55(9):1492-8. PubMed ID: 24982438
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
    Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
    Jurcic JG
    Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
    Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
    Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Jiang Z; Revskaya E; Fisher DR; Dadachova E
    Curr Radiopharm; 2018; 11(3):215-222. PubMed ID: 29683101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.
    Geerlings MW; Kaspersen FM; Apostolidis C; van der Hout R
    Nucl Med Commun; 1993 Feb; 14(2):121-5. PubMed ID: 8429990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actinium-225 in targeted alpha-particle therapeutic applications.
    Scheinberg DA; McDevitt MR
    Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview of Targeted Alpha Therapy with
    Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
    Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors.
    Kennel SJ; Chappell LL; Dadachova K; Brechbiel MW; Lankford TK; Davis IA; Stabin M; Mirzadeh S
    Cancer Biother Radiopharm; 2000 Jun; 15(3):235-44. PubMed ID: 10941530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
    Vaidyanathan G; Zalutsky MR
    Curr Radiopharm; 2011 Oct; 4(4):283-94. PubMed ID: 22202151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
    Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
    Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of
    Robertson AKH; Ramogida CF; Schaffer P; Radchenko V
    Curr Radiopharm; 2018; 11(3):156-172. PubMed ID: 29658444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators.
    Antczak C; Jaggi JS; LeFave CV; Curcio MJ; McDevitt MR; Scheinberg DA
    Bioconjug Chem; 2006; 17(6):1551-60. PubMed ID: 17105236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications.
    Chappell LL; Deal KA; Dadachova E; Brechbiel MW
    Bioconjug Chem; 2000; 11(4):510-9. PubMed ID: 10898572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
    McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA
    J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Production of Ac-225.
    Engle JW
    Curr Radiopharm; 2018; 11(3):173-179. PubMed ID: 29669509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
    Rodak M; Dekempeneer Y; Wojewódzka M; Caveliers V; Covens P; Miller BW; Sevenois MB; Bruchertseifer F; Morgenstern A; Lahoutte T; D'Huyvetter M; Pruszyński M
    Mol Cancer Ther; 2022 Dec; 21(12):1835-1845. PubMed ID: 36129807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.